Abstract 90P
Background
Microtubule-targeting agents (MTAs) have been widely used as first- and second-line agents in various cancers for several decades. Furthermore, the value of MTAs is currently increasing due to their usefulness as combination drugs with immune checkpoint inhibitors. However, many development resources have been devoted to molecular-targeted agents, and the development of new MTAs has not progressed, leaving many patients struggling with the toxicity of existing MTAs. In other words, there is an urgent need to develop new microtubule inhibitors with high cancer-specificity.
Methods
Time-lapse images were taken every 2-3 minutes for 24-72 hours. Microtubules nucleated from GMPCPP-stabilized seeds were prepared and imaged using total internal reflection fluorescence (TIRF) microscopy (Ecklund KH et al. Nature Comm 2017 ). Tubulin polymerization activity, Trans-well migration assay were measured using the HTS-Tubulin Polymerization Assay Biochem Kit (Denver, CO, USA), CytoSelect 24-well cell invasion assay kits (Cell Biolabs). Orthotopic breast cancer model (MDA MB 231) and treatment - CMPD1 (i.p., 15 μg/mouse/inj, 10 times for 3 wks), Taxol (i.p., 5 mg/kg/inj, 10 times for 3 wks) were performed. Vascular invasion was identified by tumor cells within vessels in HE staining. RNAs Sequencing libraries were prepared with the TruSeq stranded mRNA kit and sequenced on NovaSeq6000 at Macrogen Japan.
Results
CMPD1, a known inhibitor of MAP kinase-activated protein kinase 2(MK2), rapidly induces microtubule depolymerization in several cancer cell-lines, resulting in robust prometaphase arrest. CMPD1 levels alter the fate of cancer cells, either inducing mitotic slippage or resulting in mitotic defects. CMPD1 inhibits microtubule polymerization and specifically induces microtubule depolymerization at the plus end in in vitro assays; resulting in significant inhibition of tumor growth, cancer cell migration, and invasion in both in vitro and in vivo. Furthermore, clinically relevant low doses of CMPD1 induced severe and prolonged mitotic failure specifically in cancer cells, but not in non-transformed cells, with only modest effects on microtubules in vitro.
Conclusions
CMPD1 has the potential to serve as a cancer cell-selective MTA chemotherapeutic agent.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
JSPS KAKENHI 21K08638.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
24P - Single cell transcriptomics of the immune cells during chemotherapy in triple-negative breast cancer patients
Presenter: Anastasia Frolova
Session: Poster session 09
25P - Role of AXL activation on adaptive resistance to KRAS-G12C inhibitors in KRAS-G12C-mutated non-small cell lung cancer
Presenter: Tadaaki Yamada
Session: Poster session 09
26P - Pre-clinical modelling and treatment of BRAF mutated colorectal cancer
Presenter: Mark White
Session: Poster session 09
27P - Extending a classification system for atypical BRAF mutations to improve targeted therapies in colorectal cancer cells
Presenter: Abhinav Madduri
Session: Poster session 09
28P - Xanthine oxidase as a prognostic factor in colorectal cancer metastatic disease
Presenter: Anton Burlaka
Session: Poster session 09
29P - The effect of cancer associated fibroblast-derived activin A on colorectal cancer progression
Presenter: Simone Stang
Session: Poster session 09
30P - Prostaglandin signaling in tumour stroma interaction in colorectal cancer and its impact on the secretome and functional relevance
Presenter: Mario Macia-Guardado
Session: Poster session 09
31P - Cell-free tumor microRNA as early biomarkers of high-grade cervical intraepithelial neoplasia using liquid biopsy
Presenter: Stéphanie Calfa
Session: Poster session 09
32P - Epigenetic reprogramming induced prostaglandin E2 accumulation via overactivated arachidonic acid metabolism during trastuzumab resistance formation of HER2-positive breast cancer
Presenter: yongmei yin
Session: Poster session 09
33P - Visualizing trastuzumab-deruxtecan action in HER2+ breast cancer cells at nanoscale
Presenter: Katia Cortese
Session: Poster session 09